We channel decades of biologics expertise through our integrated Pharmaceutical Development & Manufacturing platform and dedicated Drug Substance Development center to accelerate monoclonal antibody (mAb) programs. By uniting deep scientific insight with proven CMC discipline, we safeguard quality and compress timelines from early feasibility to investigational supply, giving partners a strategic edge in competitive biological markets.
Overview of Monoclonal Antibody Development
Monoclonal antibodies have matured into precision macromolecules that combine selectivity, long systemic residence, and configurable effector profiles. Successful development now hinges on data-driven sequence engineering, high-titer mammalian expression systems, platformizable purification, and traceable analytics. We deploy AI-guided liability screening, modular CHO platforms, multivariate DoE, and orthogonal comparability assays to generate manufacturing-ready material with robust quality attributes. Continuous feedback loops between upstream, downstream, and analytical scientists allow rapid root-cause analysis and real-time process optimization. This holistic approach mitigates risk, supports global quality submissions, and positions each candidate for seamless expansion into late-phase campaigns.
Our Monoclonal Antibody Development Services
Our end-to-end CDMO offering focuses on four core antibody engineering services that integrate seamlessly with cell-line creation, process development, and GMP manufacture downstream.
We deliver a science-driven CDMO platform that transforms chimeric, humanized, bispecific monoclonal antibodies and antibody fragment into regulatory-ready drug substance. Agile teams, advanced analytics, and a QbD mindset compress timelines, control risk, and empower innovation—reach out to explore partnership.
Frequently Asked Questions
Q1: How do you mitigate sequence liabilities during antibody engineering?
We run parallel in-silico and wet-lab liability screens—identifying deamidation hot spots, isomerization-prone Asp-Gly motifs, N-linked glycan sequons, and aggregation patches. Advanced algorithms predict structural impact; targeted mutagenesis then removes liabilities while preserving paratope geometry. Each variant proceeds through rapid transient expression for confirmatory thermostability and binding assays, ensuring only liability-free sequences reach stable-pool generation.
Q2: What approaches secure correct chain pairing in bispecific antibodies?
Knob-into-hole Fc engineering is paired with common light-chain or CrossMab heavy-chain crossover formats. We verify pairing fidelity through native mass spectrometry and differential scanning fluorimetry, while proprietary heterodimer-selective protein-A resins remove mis-paired species. Early micro-bioreactor screens assess differential expression kinetics, guiding promoter balancing to maintain equimolar heavy-chain production.
Our products and services are for research use only.
